There is no approved retatrutide dosage. Every number online traces back to a few trial protocols. Here is the real ladder - 2 to 12 mg - what each rung delivered, and where the benefit curve flattens.
There is no approved retatrutide dosage. Not in the United States, not in Europe, not anywhere. Every number circulating in forums, spreadsheet ladders, and peptide-shop charts traces back to a handful of Eli Lilly trial protocols — and those protocols are more interesting than the charts that copy them. The trials did not test "retatrutide" as a single dose. They tested a fixed climbing schedule, and the space between the doses is where the actual story lives.
So here is what the protocols really used, week by week, what each rung delivered, and why the top of the ladder is the least interesting part of it.
The first human dose-response data came from the phase 2 obesity trial, published in the New England Journal of Medicine in 2023. It randomized 338 adults to once-weekly injections of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks. Two design details matter more than the headline. First, the higher-dose arms did not start at their target: the 8 mg arm began at either 2 mg or 4 mg, and the 12 mg arm began at 2 mg. Second, gastrointestinal side effects were dose-related and were partially mitigated by the lower 2 mg start compared with 4 mg. The ladder itself was the safety intervention.
The results tracked the ladder. At 24 weeks, average weight change was -7.2% on 1 mg, -12.9% on 4 mg, -17.3% on 8 mg, and -17.5% on 12 mg, against -1.6% on placebo. At 48 weeks the same arms read -8.7%, -17.1%, -22.8%, and -24.2%, against -2.1%. Heart rate rose dose-dependently, peaked around week 24, and declined thereafter — a reminder that the body's response to this molecule is not a straight line.
The registrational TRIUMPH program replaced the phase 2 arms with a single fixed staircase. Published trial methods and Lilly's study releases describe the same schedule: every phase 3 participant started at 2 mg once weekly, and the dose stepped up every four weeks until the assigned target was reached. The 4 mg arm went 2 → 4. The 9 mg arm went 2 → 4 → 6 → 9. The 12 mg arm went 2 → 4 → 6 → 9 → 12. The 6 mg strength exists only as a rung; no trial ever tested it as a maintenance dose.
Put on a calendar, that means the 4 mg arm reached its target in week 5, the 9 mg arm in week 13, and nobody reached 12 mg before week 17. The design paper is explicit about the shape of the study: 16 weeks of dose escalation followed by 64 weeks of maintenance, 80 weeks in total. TRIUMPH-1 and TRIUMPH-2 randomized participants to 4, 9, or 12 mg or placebo. TRIUMPH-3 (a weight trial in people with established cardiovascular disease) and TRIUMPH-4 (a knee-osteoarthritis trial) dropped the 4 mg arm entirely and tested only 9 and 12 mg.
Why once a week at all? Pharmacokinetics. Retatrutide is dose-proportional with a mean half-life of roughly six days, which is what makes a weekly injection and a four-week step interval reasonable. It is also why a missed week is not a trivial event: the molecule is still very much present.
TRIUMPH-1 enrolled 2,339 adults with obesity and no diabetes, mean baseline weight 112.7 kg. In the peer-reviewed New England Journal paper, average weight change at 80 weeks was -17.6% on 4 mg, -23.7% on 9 mg, and -25.0% on 12 mg, against -3.9% on placebo. Lilly's earlier topline efficacy analysis, which assumes participants stayed on treatment, read the same trial as -19.0%, -25.9%, and -28.3% against -2.2%. Both numbers are honest; they answer different questions. The journal figures fold in what happens when people stop, the efficacy analysis asks what the drug does while people take it. When a headline says retatrutide produces "25%" or "28%" weight loss, this accounting choice is usually the difference.
At the top dose, the distribution is striking: 62.5% of the 12 mg group lost at least 25% of their body weight, 45.3% lost at least 30%, and 27.2% lost at least 35%, against 2.2%, 0.5%, and 0.3% on placebo. In a blinded extension, 532 completers who moved to maximum tolerated dose averaged 30.3% loss — about 38.5 kg — by week 104.
TRIUMPH-2 ran the same three doses in 1,152 adults with obesity and type 2 diabetes, and the curve shifted down: -11.9%, -16.8%, and -18.8% against -5.1% on placebo. Our TRIUMPH results breakdown covers the knee-pain and sleep-apnea findings in that program in more detail. TRANSCEND-T2D-1, a 40-week monotherapy trial in 537 people whose diabetes was controlled by diet and exercise alone, reported HbA1c reductions of -1.69%, -1.86%, and -1.94% against -0.81%, with weight changes of -11.5%, -13.9%, and -15.3% against -2.6%. Our TRANScend-T2D write-up walks through those results.
Compare the rungs rather than the headlines. In TRIUMPH-1, moving from 4 mg to 9 mg bought roughly six percentage points of additional weight loss. Moving from 9 mg to 12 mg bought about one. In TRIUMPH-2 the same step bought about two. In the diabetes trial it was a point and a half. The steepest part of the dose-response curve is behind the 9 mg rung.
Side effects do not flatten the same way. In the TRIUMPH-1 topline safety data, nausea ran 28.6%, 38.4%, and 42.4% across the three doses against 14.8% on placebo; vomiting ran 10.6%, 22.8%, and 25.3% against 4.8%. TRIUMPH-2's peer-reviewed paper adds an odd detail: permanent discontinuations due to adverse events were 4% in the 4 mg group, 12% in the 9 mg group, and 8% in the 12 mg group, against 5% on placebo. More people quit at 9 mg than at 12 mg. That is not a typo, and it is a useful corrective to the idea that higher is simply harder — tolerability is individual, and the middle rung is where many people decide.
Both trials also report dysesthesia (tingling or altered sensation) and hypotension at higher rates than placebo — the kind of findings that never make it into the promotional charts.
The published protocols contain escape hatches that no gray-market ladder includes. The TRIUMPH design paper allows a permanent dose reduction for gastrointestinal side effects or inadequate oral intake that does not improve with other mitigations — including, notably, a de-escalation and re-escalation attempt first. Dose reduction is also allowed for anyone reaching a BMI of 22 or lower, or perceiving excessive weight loss. In other words, the people designing the trials expected real humans to need off-ramps, and built them in.
The same protocols were also run with pharmaceutical-grade product under double-blind conditions with clinical monitoring. Whatever a research-chemical vial contains is a separate question from what these numbers mean — our piece on what is actually in a research vial covers why identity, purity, and dose accuracy are their own problem. Trial doses are not prescriptions. They are descriptions of what happened to specific groups of people under specific conditions.
The useful insight from five years of retatrutide dosing data is not the top number. It is the shape: a slow 2 mg start that measurably reduces the side effects that make people quit, a steep gain through the middle rungs, and a thin final increment at 12 that trades against nausea and dropout. The trials treated the ladder as part of the medicine. Anyone quoting you a target dose without the schedule attached is quoting half a protocol.
Retatrutide remains investigational and unapproved. The evidence behind these numbers is strong as trial evidence goes — multiple phase 3 programs, pre-registered endpoints, thousands of participants — but it is entirely manufacturer-funded, and the dose that will eventually be approved, if any, will be a regulatory decision rather than a scientific one.
Evidence Grade: B+. Two independently published phase 3 randomized controlled trials and one phase 3 diabetes trial back the per-dose figures, with clear dose-response relationships and pre-registered endpoints. Downgraded from A because every trial is manufacturer-funded, the most-cited top-line figures depend on estimand choices, retatrutide is unapproved, and the titration ladder itself is documented through study releases and design papers rather than a full public protocol. Sources Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526 (NCT04881760). Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026 Sep 29. doi:10.1056/NEJMoa2604169 (TRIUMPH-1, NCT05929066). Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2). Lancet. 2026;408(10563):1455-1472 (NCT05929079). Bajaj HS, et al. Efficacy and safety of retatrutide in people with type 2 diabetes (TRANSCEND-T2D-1). Lancet. 2026;407(10546):2402-2413 (NCT06354660). Giblin K, et al. Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(1):83-93. Grunstein RR, et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. N Engl J Med. 2026 Oct 21. Tetelbaun L, et al. The First Triple Agonist for Antiobesity: Retatrutide. Cardiol Rev. 2026;34(6):575-579. Titration schedule as published by Eli Lilly study releases (Dec 2025 - Jul 2026), reported by HCPLive, May 21, 2026.
Medical Disclaimer This article is for educational purposes only and is not medical advice. Retatrutide is an investigational compound that has not been approved by the FDA and is not legally available as a prescribed medication. The doses described here are what clinical trial protocols used; they are not recommendations. Nothing here should be read as a recommendation to seek out, purchase, or use any unapproved substance. Talk to a licensed physician before making any decision about your health. That is also why Oria exists: the evidence deserves careful reading, and careful reading is a poor substitute for clinical care.
